|
(1) |
Includes $1.5 million, $1.2 million, $2.7 million, and $2.5 million, respectively, in cost of revenues for the periods presented. |
|
(2) |
Primarily includes $16.4 million for the hedging loss related to the Australian dollar purchase price for Sirtex Medical Limited. |
|
(3) |
Represents the tax effect of a change in law related to the U.S. Tax Cuts and Jobs Act. The corporate rate reduction results in a remeasurement of our Deferred Tax Assets of $2.5 million in the second quarter and $40.2 million in the year-to-date period. The mandatory deemed repatriation of unremitted foreign earnings results in an estimated charge of $3.7 million in the second quarter and $173.1 million in the year-to-date period. |
|
(4) |
Excludes immaterial net earnings (loss) from continuing operations attributable to noncontrolling interests for the periods presented. |
